ICU: QUELIMMUNE sales surged as adult AKI trial enrollment advanced to 251 patients
SeaStar Medical (ICU) reported Q3 revenue of $635K, up 247% YoY, with gross margins above 90%. Net loss widened to $4.529M. The NEUTRALIZE-AKI trial enrolled 251 of 339 patients, and the first PMA module was submitted to the FDA.
How this was made

The 30-second read
Why it matters
The disclosed revenue surge and trial enrollment progress provide fresh material for traders evaluating the stock's upside potential.
Market read
New financial and clinical data could trigger a short‑term price rally.
What to watch
The company still reports a widening net loss, which may temper enthusiasm.
Background
SeaStar Medical Holding Corp (ICU) filed an 8‑K reporting Q3 results and clinical trial milestones.
Ticker impact
Q3 revenue rose 247% YoY to $635K and trial enrollment reached 251 patients, with a PMA module submitted to the FDA.
likely upward pressure as investors price in the chance of FDA clearance and higher sales.
Clinical progress and a filing for a PMA are material catalysts for a biotech micro‑cap, often driving share price gains.
Market effects
Positive signal for the renal‑failure biotech sector, may lift peer valuations.
US biotech market sees modest uplift.
Limited to investors tracking niche AKI therapeutics.
Counterpoint
If the FDA requires additional data, the current optimism could reverse quickly.
Key entities
- companySeaStar Medical Holding Corp
US‑listed biotech focused on acute kidney injury treatments.